DrugPatentWatch Database Preview
Drugs in Development Information for Afuresertib
What is the drug development status for Afuresertib?
Afuresertib is an investigational drug.
There have been 8 clinical trials for Afuresertib.
The most recent clinical trial was a Phase 1 trial, which was initiated on August 1st 2015.
The most common disease conditions in clinical trials are Neoplasms, Plasma Cell, Multiple Myeloma, and Prostatic Neoplasms. The leading clinical trial sponsors are GlaxoSmithKline, Novartis Pharmaceuticals, and National Cancer Institute (NCI).
There are thirteen US patents protecting this investigational drug and one hundred and seventy-four international patents.
Summary for Afuresertib
| US Patents | 13 |
| International Patents | 174 |
| US Patent Applications | 64 |
| WIPO Patent Applications | 25 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 1 (2015-08-01) |
| Vendors | 30 |
Recent Clinical Trials for Afuresertib
| Title | Sponsor | Phase |
|---|---|---|
| Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC | Laekna Limited | Phase 1/Phase 2 |
| Dose-Finding Study of Afuresertib Administered in Combination With Either Enzalutamide or Aibraterone | GlaxoSmithKline | Phase 1 |
| A Study Looking at Targeted Therapy According to Tumor Markers for People With Meningiomas | Brain Science Foundation | Phase 2 |
Clinical Trial Summary for Afuresertib
Top disease conditions for Afuresertib
Top clinical trial sponsors for Afuresertib
US Patents for Afuresertib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Afuresertib | Start Trial | Inhibitors of Akt activity | GlaxoSmithKline LLC (Philadelphia, PA) | Start Trial |
| Afuresertib | Start Trial | Inhibitors of Akt activity | GlaxoSmithKline LLC (Philadelphia, PA) | Start Trial |
| Afuresertib | Start Trial | Pharmaceutical composition | GlaxoSmithKline LLC (Philadelphia, PA) | Start Trial |
| Afuresertib | Start Trial | Chemical compounds | GlaxoSmithKline LLC (Philadelphia, PA) | Start Trial |
| Afuresertib | Start Trial | Crystalline N-{(1S)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-m- ethyl-1H-pyrazol-5-yl)-2-thiophenecarboxamic hydrochloride | GlaxoSmithKline LLC (Philadelphia, PA) | Start Trial |
| Afuresertib | Start Trial | Combination of a B-Raf inhibitor: N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1- dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfo- namide and the Akt inhibitor: N-{ (1S)-2-amino-1-[(3- fluorophenyl)methyl]ethyl}-5-chIoro-4-(4-chIoro- 1 -methyl- 1 H-pyrazol-5-yl)-2-10 thiophenecarboxamide useful in the treatment of cancer | GlaxoSmithKline LLC (Wilmington, DE) | Start Trial |
| Afuresertib | Start Trial | Inhibitors of AkT activity | GlaxoSmithKline LLC (Wilmington, DE) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Afuresertib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Afuresertib | Argentina | 066184 | 2027-02-07 | Start Trial |
| Afuresertib | Australia | 2008213694 | 2027-02-07 | Start Trial |
| Afuresertib | Brazil | PI0807146 | 2027-02-07 | Start Trial |
| Afuresertib | Canada | 2678255 | 2027-02-07 | Start Trial |
| Afuresertib | Chile | 2008000348 | 2027-02-07 | Start Trial |
| Afuresertib | China | 101646427 | 2027-02-07 | Start Trial |
| Afuresertib | Colombia | 6220930 | 2027-02-07 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
